Emery Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Emery Pharma is a privately held, revenue-generating CRO offering a comprehensive suite of laboratory and consulting services to pharmaceutical and biotechnology clients. Its core business model is providing outsourced R&D services, including method development, impurity analysis, biologics characterization, and specialized antimicrobial testing. The company leverages state-of-the-art analytical equipment and a quality-focused system to deliver regulatory-grade data, positioning itself as a partner for drug development from discovery through to litigation support.

Drug DeliverySmall Molecules

Technology Platform

Integrated suite of analytical technologies (LC-MS, GC-MS, HPLC, NMR, HRMS) and microbiological assays for pharmaceutical testing, characterization, and bioanalysis under GLP/cGMP standards.

Opportunities

Growth is driven by increasing outsourcing of complex analytical work, rising demand for biologics and gene therapy characterization, and heightened regulatory focus on impurities like nitrosamines.

The antimicrobial resistance crisis also fuels need for specialized microbiology testing services.

Risk Factors

Key risks include intense competition from other CROs, dependence on cyclical biopharma R&D spending, and the constant need for capital investment to maintain state-of-the-art equipment.

Regulatory compliance failures could severely damage reputation.

Competitive Landscape

Emery Pharma competes in the fragmented analytical CRO market against large global players (e.g., LabCorp, Charles River) and numerous small, niche laboratories. It differentiates through specialized services like nitrosamine testing, antimicrobial synergy studies, and litigation support, targeting small-to-mid sized biopharma companies.

More companies in Digital Health & Biotech SaaS →More companies in United States →